Trogocytosis of MHC-I/peptide complexes derived from tumors and infected cells enhances dendritic cell cross-priming and promotes adaptive T cell responses.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: Electronic Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Major Histocompatibility Complex*; Dendritic Cells/*immunology ; Histocompatibility Antigens Class I/*immunology ; Infections/*immunology ; Neoplasms/*immunology ; T-Lymphocytes/*immunology; Adaptation, Biological/immunology ; Animals ; Antigen-Presenting Cells/immunology ; Cross-Priming/immunology ; Gamma Rays ; Histocompatibility Antigens Class I/radiation effects ; Humans ; Mice ; T-Lymphocytes/radiation effects ; T-Lymphocytes, Cytotoxic/immunology

The transporter associated with antigen processing (TAP) and the major histocompatibility complex class I (MHC-I), two important components of the MHC-I antigen presentation pathway, are often deficient in tumor cells. The restoration of their expression has been shown to restore the antigenicity and immunogenicity of tumor cells. However, it is unclear whether TAP and MHC-I expression in tumor cells can affect the induction phase of the T cell response. To address this issue, we expressed viral antigens in tumors that are either deficient or proficient in TAP and MHC-I expression. The relative efficiency of direct immunization or immunization through cross-presentation in promoting adaptive T cell responses was compared. The results demonstrated that stimulation of animals with TAP and MHC-I proficient tumor cells generated antigen specific T cells with greater killing activities than those of TAP and MHC-I deficient tumor cells. This discrepancy was traced to differences in the ability of dendritic cells (DCs) to access and sample different antigen reservoirs in TAP and MHC-I proficient versus deficient cells and thereby stimulate adaptive immune responses through the process of cross-presentation. In addition, our data suggest that the increased activity of T cells is caused by the enhanced DC uptake and utilization of MHC-I/peptide complexes from the proficient cells as an additional source of processed antigen. Furthermore, we demonstrate that immune-escape and metastasis are promoted in the absence of this DC 'arming' mechanism. Physiologically, this novel form of DC antigen sampling resembles trogocytosis, and acts to enhance T cell priming and increase the efficacy of adaptive immune responses against tumors and infectious pathogens.

J Immunol. 2000 Mar 1;164(5):2354-61. (PMID: 10679070)
J Immunol. 1999 Oct 15;163(8):4224-31. (PMID: 10510359)
J Immunol. 2000 May 1;164(9):4968-78. (PMID: 10779808)
Behring Inst Mitt. 1994 Jul;(94):37-47. (PMID: 7998912)
Eur J Immunol. 2005 Aug;35(8):2284-94. (PMID: 16021601)
J Immunol. 2004 Oct 15;173(8):4828-37. (PMID: 15470023)
J Immunol. 1993 Sep 15;151(6):2974-85. (PMID: 8397249)
Int J Cancer. 2006 Apr 15;118(8):1984-91. (PMID: 16284959)
J Immunol. 2003 May 1;170(9):4515-23. (PMID: 12707328)
Nature. 1999 Mar 4;398(6722):77-80. (PMID: 10078533)
Int J Cancer. 1999 Mar 31;81(1):125-33. (PMID: 10077163)
Annu Rev Immunol. 2001;19:47-64. (PMID: 11244030)
J Exp Med. 1994 Oct 1;180(4):1415-25. (PMID: 7931074)
Nat Immunol. 2003 Nov;4(11):1065-73. (PMID: 14566337)
J Immunol. 2000 May 1;164(9):4513-21. (PMID: 10779752)
Nat Med. 2001 Dec;7(12):1306-12. (PMID: 11726970)
J Immunol. 2003 Feb 15;170(4):1822-9. (PMID: 12574347)
PLoS Pathog. 2005 Dec;1(4):e36. (PMID: 16389301)
J Cell Biol. 1998 Jan 12;140(1):17-27. (PMID: 9425150)
J Immunol. 2001 Nov 1;167(9):5420-8. (PMID: 11673561)
J Immunol. 1994 Jan 15;152(2):381-7. (PMID: 8283027)
Cell Immunol. 2004 Apr;228(2):130-7. (PMID: 15219464)
Immunol Today. 1997 Jun;18(6):292-9. (PMID: 9190116)
J Exp Med. 1992 Dec 1;176(6):1693-702. (PMID: 1460426)
Nat Biotechnol. 2000 May;18(5):515-20. (PMID: 10802618)
Nat Rev Immunol. 2001 Nov;1(2):126-34. (PMID: 11905820)
Front Biosci. 2002 Mar 01;7:d731-51. (PMID: 11861214)
Cancer Res. 2005 Sep 1;65(17):7926-33. (PMID: 16140964)
Eur J Immunol. 1995 May;25(5):1374-84. (PMID: 7774641)
Cancer Sci. 2004 Mar;95(3):248-53. (PMID: 15016325)
Immunity. 2000 Dec;13(6):841-51. (PMID: 11163199)
J Cell Physiol. 2003 Jun;195(3):346-55. (PMID: 12704644)
Proc Natl Acad Sci U S A. 1988 Jun;85(12):4463-7. (PMID: 3380801)
J Exp Med. 1994 Apr 1;179(4):1215-24. (PMID: 7908321)
Immunol Today. 2000 Sep;21(9):455-64. (PMID: 10953098)
J Immunol. 1999 Jul 1;163(1):130-6. (PMID: 10384108)
Int J Cancer. 2007 May 1;120(9):1935-41. (PMID: 17278102)
Cancer Immun. 2003 Jan 28;3:1. (PMID: 12747743)
J Immunol. 2002 Nov 15;169(10):5424-32. (PMID: 12421917)
Adv Immunol. 1998;68:191-256. (PMID: 9505090)
Science. 1994 May 13;264(5161):961-5. (PMID: 7513904)
J Exp Med. 1991 Aug 1;174(2):489-92. (PMID: 1856631)

0 (Histocompatibility Antigens Class I)

Date Created: 20080905 Date Completed: 20081218 Latest Revision: 20211020

20231215

PMC2518214

10.1371/journal.pone.0003097

18769733